港股嘉和生物-B（06998）今日盘中大涨5.30%，引发市场关注。该涨幅与公司重要新药获批有关。
据悉，中国国家药品监督管理局（NMPA）已批准嘉和生物的来罗西利（GB491）新药上市申请。来罗西利是一种用于治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌成人患者的药物。该药可与芳香化酶抑制剂联合使用作为初始内分泌治疗，或与氟维司群联合用于既往接受内分泌治疗后疾病进展的患者。
这一批准标志着嘉和生物在肿瘤治疗领域取得重大突破。新药的获批不仅有望为相关患者带来新的治疗选择，也可能为公司带来新的收入来源，推动公司业务发展。投资者对此反应积极，推动股价大幅上涨。后市表现仍需持续关注公司新药的商业化进展及市场反响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.